Celwise AB Uses ExOne 3D Printed Tooling to Transform Wood Fiber into Innovative, Single-Use Plastic Replacement
7.9.2021 15:30:00 EEST | Business Wire | Press release
The ExOne Company (Nasdaq: XONE), the global leader in industrial sand and metal 3D printers using binder jetting technology, is proud to announce that innovative molded fiber technology supplier, Celwise AB of Norrköping, Sweden, is using metal tools 3D printed by ExOne in 316L stainless steel for its patented method of transforming wood and other cellulose fibers into a wide range of eco-friendly packaging and products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005199/en/
Celwise's innovative and sustainable molded fiber products, which replace single-use plastics, are shown in front of the X1 160Pro™ production metal 3D printer. A key part of Celwise’s patented production method for producing this all-new type of molded fiber product is uniquely featured metal tooling that can only be made with additive manufacturing, such as ExOne’s binder jetting technology. (Photo: Business Wire)
Invented, developed and patented over the past 10 years, Celwise technology aims to transform the paper and plastics industry with its innovation, which produces a water-resistant molded fiber product that looks and feels like a luxurious blend of wood and plastic. Celwise technology is enjoying rapid success, with adoption projects now underway with a wide range of global companies serving many industries, including consumer products, food and beverage, cosmetics, and electronics.
“Our planet needs this technology now,” said David Pierce, Inventor and Co-Owner of Celwise. “Our patented technology delivers a recyclable, renewable, and biodegradable product that can be manufactured faster and more affordably than traditional technologies. Advanced manufacturing approaches, which rely on 3D printed tooling from ExOne, are an important part of our process.”
“Celwise is demonstrating how new technologies such as binder jet 3D printing can help solve some of the world’s toughest problems,” said John Hartner, ExOne’s CEO. “We’re proud to collaborate with Celwise on delivering this important innovation.”
How it Works
Celwise’s patented process includes unique tooling and machines, as well as a novel process, to deliver its final product. Common cellulose fiber-based (paper) product manufacturing slowly removes water from cellulose fiber for molded products that must be coated for water resistance.
Celwise, however, rapidly removes water in a new process that enables cellulose fibers to re-bond with each other quickly, creating a new type of paper product that is strong, wood-like, and water-resistant.
What’s more, because a series of forming, transferring and pressing tools are 3D printed using ExOne binder jetting technology, the process gives Celwise even more design freedom to develop their client’s products.
ExOne’s binder jet 3D printing transforms powdered materials — metal, sand or ceramic — into highly dense and functional precision parts at high speeds. An industrial printhead selectively deposits a binder into a bed of powder particles creating a solid part one thin layer at a time, similar to printing on sheets of paper.
When printing metals, such as the Celwise tools, the final bound metal part must be sintered in a furnace to fuse the particles together into a solid object. Binder jet 3D printing technology is viewed as a desirable and sustainable production method, largely because of its high speed, low waste and cost, as well as material flexibility.
ExOne is now providing prototype and production tools to Celwise specifications. While other metal 3D printing processes can produce the types of tools required by Celwise, Pierce estimates that ExOne binder jetting technology delivers a 20% time savings over those processes as well as a cost savings of 30-40%.
About ExOne
ExOne (Nasdaq: XONE) is the pioneer and global leader in binder jet 3D printing technology. Since 1995, we’ve been on a mission to deliver powerful 3D printers that solve the toughest problems and enable world-changing innovations. Our 3D printing systems quickly transform powder materials — including metals, ceramics, composites and sand — into precision parts, metalcasting molds and cores, and innovative tooling solutions. Industrial customers use our technology to save time and money, reduce waste, improve their manufacturing flexibility, and deliver designs and products that were once impossible. As home to the world’s leading team of binder jetting experts, ExOne also provides specialized 3D printing services, including on-demand production of mission-critical parts, as well as engineering and design consulting. Learn more about ExOne at www.exone.com or on Twitter at @ExOneCo. We invite you to join with us to #MakeMetalGreen™.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005199/en/
Contact information
Sarah Webster
Chief Marketing Officer
724.516.2336
sarah.webster@exone.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release
Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
